Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talquetamab in Refractory Generalized Myasthenia Gravis
NCT07499323Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Open-label, single-arm trial of talquetamab in myasthenia gravis (MG), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: Myasthenia Gravis Activities of Daily Living. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
talquetamab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07499323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07499323.